Natpara regulatory update

FDA accepted for review a BLA from NPS for Natpara to treat hypoparathyroidism. The PDUFA date is Oct. 24. The recombinant human parathyroid hormone 1-84 (PTH) has Orphan Drug designation in the U.S. for the indication. ...